Abstract

In recent years Immune Check Point Inhibitors (ICIs) have played an integral role in the treatment of a wide variety of malignancies. Despite improvements in survival outcomes with immunotherapy, immune related Adverse Events (irAEs) are increasing in incidence

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call